Small Cell Lung Cancer (SCLC)

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.

A real-world, retrospective analysis showed that CRS and ICANS occurred in 48% and 16% of patients with ES-SCLC who were treated with tarlatamab.

Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.

The frontline treatment algorithm in SCLC is poised to look “radically different” in the upcoming years, according to Anne Chiang, MD, PhD.

In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.

In patients with LS-SCLC who were ineligible for a prophylactic cranial irradiation, toripalimab appeared to decrease the progression of brain metastases.

Future biomarker analysis will include correlation of efficacy with SLFN11 expression and with markers of DNA damage repair.

Cisplatin/etoposide and carboplatin/etoposide achieved median OS of 8.8 months and 7.8 months, respectively, in those with extensive-stage small cell lung cancer.

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

Lurbinectedin achieved an ORR of 27% in all patients with extensive-stage small cell lung cancer in the phase 4 Jazz Emerge 402 study.

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.

Results from the DeLLphi-303 trial showed sustained efficacy and safety with tarlatamab plus anti–PD-1 treatment for patients with extensive-stage SCLC.

Rates of grade 3 or 4 AEs with durvalumab were similar across subgroups, with serious AEs more frequent in patients 70 years or older with ES-SCLC.

The confirmed overall response rate with ABB-706 was 77% in patients with relapsed/refractory small cell lung cancer who received 2 prior lines of therapy.

Leveraging #WCLC25, lung oncologists spoke about the presentations they’re most looking forward to at the upcoming conference.

The median overall survival with atezolizumab plus carboplatin and etoposide was 10.6 months in patients with extensive-stage small cell lung cancer.

The biomarker NLR may not be suitable for prognosis prediction in older patients with small cell lung cancer, according to findings from this real-world study.

No treatment-related deaths were observed with radiotherapy for extensive-stage small cell lung cancer, and most adverse effects were grade 1 or 2.

The median PFS and OS were 5.5 months and 11.2 months, respectively, with nivolumab plus carboplatin/cisplatin and etoposide in patients with small cell lung cancer.

Results from a retrospective study showed that chemoimmunotherapy did not prolong survival vs chemotherapy in a younger ES-SCLC population.

Patients with extensive-stage small cell lung cancer experienced a median PFS and OS of 4.5 months and 7.2 months, respectively, with anlotinib plus irinotecan.

Symptom specificity is now included in updated guidelines for SCLC relating to LEMS, characterized by proximal muscle weakness and autonomic dysfunction.

Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.